- Home
- SUPN vs CGAU Comparison
SUPN vs CGAU Comparison
Compare SUPN & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- CGAU
- Stock Information
- Founded
- SUPN 2005
- CGAU 2002
- Country
- SUPN United States
- CGAU Canada
- Employees
- SUPN N/A
- CGAU N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- CGAU Precious Metals
- Sector
- SUPN Health Care
- CGAU Basic Materials
- Exchange
- SUPN Nasdaq
- CGAU Nasdaq
- Market Cap
- SUPN 2.6B
- CGAU 2.4B
- IPO Year
- SUPN 2012
- CGAU N/A
- Fundamental
- Price
- SUPN $46.02
- CGAU $11.41
- Analyst Decision
- SUPN Strong Buy
- CGAU Buy
- Analyst Count
- SUPN 4
- CGAU 3
- Target Price
- SUPN $63.25
- CGAU $14.17
- AVG Volume (30 Days)
- SUPN 1.0M
- CGAU 1.8M
- Earning Date
- SUPN 11-04-2025
- CGAU 10-28-2025
- Dividend Yield
- SUPN N/A
- CGAU 1.93%
- EPS Growth
- SUPN N/A
- CGAU 236.39
- EPS
- SUPN N/A
- CGAU 1.60
- Revenue
- SUPN $681,539,000.00
- CGAU $1,285,392,000.00
- Revenue This Year
- SUPN $8.29
- CGAU $9.10
- Revenue Next Year
- SUPN $22.72
- CGAU $13.13
- P/E Ratio
- SUPN N/A
- CGAU $6.78
- Revenue Growth
- SUPN 4.54
- CGAU 2.66
- 52 Week Low
- SUPN $29.16
- CGAU $5.41
- 52 Week High
- SUPN $57.65
- CGAU $12.80
- Technical
- Relative Strength Index (RSI)
- SUPN 37.29
- CGAU 53.05
- Support Level
- SUPN $43.11
- CGAU $11.13
- Resistance Level
- SUPN $57.34
- CGAU $11.60
- Average True Range (ATR)
- SUPN 2.50
- CGAU 0.48
- MACD
- SUPN -0.98
- CGAU -0.10
- Stochastic Oscillator
- SUPN 19.60
- CGAU 50.00
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.